Inhibitors of platelet signal transduction as anti-aggregatory drugs

By Geiger J.  

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 5, 2001-05 ,pp. : 865-890

Informa Healthcare

Access to resources Recommend Favorite

Antiaggregatory, antithrombotic effects of MS-180, a novel platelet glycoprotein II b /III a receptor antagonist

By Banno H.   Kawazura H.   Yutaka T.   Sakuma N.   Kitamori T.   Hosoya J.   Kibayashi K.   Yamashita H.   Umemura K.   Nakashima M.  

European Journal of Pharmacology, Vol. 367, Iss. 2, 1999-02 ,pp. : 275-282

Elsevier

Access to resources Recommend Favorite

Neuropeptide Y1 and Y5 Receptor Antagonists as Potential Anti-Obesity Drugs: Current Status

By  

Mini Reviews in Medicinal Chemistry, Vol. 14, Iss. 11, 2014-10 ,pp. : 896-919

Bentham Science Publishers

Access to resources Recommend Favorite

NPY Y1 and Y5 Receptor Selective Antagonists as Anti-Obesity Drugs

By  

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 17, 2007-01 ,pp. : 1721-1733

Bentham Science Publishers

Access to resources Recommend Favorite

Platelet glycoprotein IIb/IIIa receptor antagonists

By Casserly I.P.   Moliterno D.J.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 3, 2000-03 ,pp. : 419-433

Informa Healthcare

Access to resources Recommend Favorite